Abzena Strengthens Leadership with New Board Appointment
Abzena has recently announced a strategic addition to its Board of Directors with the appointment of Dr. Moncef Slaoui, a distinguished leader in the biopharmaceutical field. With over 40 years of experience, Dr. Slaoui’s leadership is expected to greatly assist the company in navigating the challenges of drug development while enhancing its position in the market.
Dr. Moncef Slaoui's Impressive Background
Dr. Slaoui’s career showcases a wealth of experience he gained through various executive roles, underscoring his capability in steering companies through transformative periods. Prior to joining Abzena, he was instrumental in numerous biopharmaceutical initiatives and held executive positions at reputed organizations. His appointment is seen as a pivotal step for Abzena as it continues to solidify its reputation in the development and manufacturing of complex biologics.
CEO Matt Stober on the Appointment
Matt Stober, CEO of Abzena, expressed enthusiasm regarding Dr. Slaoui's addition, stating that his unparalleled track record in leadership and product innovation will be integral to Abzena’s growth strategy. Stober emphasized the value of Dr. Slaoui’s experience, noting how it aligns with the company’s goals of becoming a frontrunner in drug development.
Dr. Slaoui's Vision for Abzena
Upon his appointment, Dr. Slaoui conveyed his excitement about joining Abzena, highlighting the company’s innovative approaches in the CRO and CDMO sectors. He anticipates collaborating with the team to drive the advancement of new technologies that enhance how next-generation therapeutics are delivered.
Chairman Geoffrey Glass Welcomes Dr. Slaoui
Geoffrey Glass, Chairman of Abzena’s Board, warmly welcomed Dr. Slaoui, noting the significance of his extensive expertise in the biotechnology industry. Glass is optimistic about the direction Abzena will take with Dr. Slaoui onboard, particularly as it prepares for its next phase of growth and innovation.
Dr. Slaoui's Previous Achievements
Dr. Slaoui currently serves as an advisor to Medicxi and is involved with several organizations, including Cedar Health and Arcturus Therapeutics. His prior experience also includes holding board positions at well-known biopharma companies, such as Moderna and Lonza Group. His leadership during the pandemic as the Chief Scientific Advisor to Operation Warp Speed was crucial in the rapid development of COVID-19 vaccines.
Academic Credentials
Dr. Slaoui holds a PhD in Molecular Biology and Immunology from Université Libre de Bruxelles, along with postdoctoral studies from renowned institutions like Harvard Medical School and Tufts University. He further enhances his qualifications with an accelerated MBA from IMD in Switzerland.
About Abzena
Abzena stands as a premier end-to-end service provider in the bioconjugate and complex biologics sectors, specializing in CDMO and CRO services. The company is committed to guiding customers from the discovery phase through to commercial launch of their products. With a focus on customized strategies, Abzena’s innovative solutions empower biotech and biopharma companies to efficiently advance their therapies. The organization's facilities span across research and development centers, with locations in San Diego, Bristol, and Cambridge. Abzena is backed by Welsh, Carson, Anderson & Stowe, a leading private equity firm dedicated to fostering growth in the biopharmaceutical industry.
Frequently Asked Questions
What qualities does Dr. Slaoui bring to Abzena?
Dr. Slaoui brings extensive experience in biopharmaceutical development, leadership skills, and a track record of innovation that will support Abzena's growth.
What role did Dr. Slaoui play during the COVID-19 pandemic?
He served as the Chief Scientific Advisor to Operation Warp Speed, overseeing the rapid development and deployment of multiple vaccines.
Where is Abzena headquartered?
Abzena has facilities in San Diego, Bristol, and Cambridge, providing a comprehensive support system for its clients.
What does Abzena specialize in?
Abzena specializes in offering end-to-end services for bioconjugates and complex biologics, including both CDMO and CRO services.
Who is the chairman of Abzena's Board of Directors?
The chairman of Abzena's Board is Geoffrey Glass, who welcomes new board members focused on driving the company's growth.
